Cannabinoids in Medicine: Limitless Hope or Hype?

What is the role of cannabinoids as an intoxicant and in medical applications today? This was the question addressed by Dieter Braus, MD, psychiatrist and neurologist at Vitos Clinic Rheingau in Eltville, Germany, at the DGIM Congress 2022. Dampening the Dopamine System Regardless of the type of substance-dependent addiction — whether alcohol, opiates, nicotine, or … Read more

Running to the Top: Exercise and Mental Health

An apple a day keeps the doctor away! We’ve probably been given this advice or know of others who have been given this advice time and time again… to eat healthier, and more important, to exercise. While exercise is not necessarily the cure-all for the world’s infections and diseases, it plays an important role in … Read more

Burnout ‘Highly Prevalent’ in Psychiatrists Across the Globe

Burnout in psychiatrists is “highly prevalent” across the globe, new research shows. In a review and meta-analysis of 36 studies and more than 5000 psychiatrists in European countries, as well as the United States, Australia, New Zealand, India, Turkey, and Thailand, results showed that 25% of respondents met criteria for burnout, as measured by the … Read more

Does Metformin Blunt Diabetes Link to Brain Aging?

researchers published the study covered in this summary on medRxiv.org as a preprint that has not yet been reviewed. Key Takeaways Type 2 diabetes appears to significantly accelerate normal brain aging. Metformin use does not appear to prevent neurocognitive decline. Why This Matters Although preliminary evidence links type 2 diabetes to neurologic and cognitive decline, … Read more

Brief Intervention Effective, Durable for Schizophrenia

Metacognitive training (MCT) is effective in reducing positive and negative symptoms of schizophrenia, new research suggests. MCT for psychosis is a brief intervention that “combines psychoeducation, cognitive bias modification, and strategy teaching but does not directly target psychosis symptoms.” Results from a meta-analysis of 40 studies with more than 1,800 total participants with schizophrenia showed … Read more

Placebo Response in Neuropathic Pain Trials

The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways Both placebo and nocebo effects can greatly affect the interpretation of outcomes in randomized controlled trials of chronic neuropathic pain treatments. When trials are being designed and interpreted, these effects need to be … Read more

Promising Disease Markers in Amyotrophic Lateral Sclerosis

The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways Seven nerve excitability indices distinguish patients with amyotrophic lateral sclerosis (ALS) from healthy controls. Four indices may be biomarkers of early stage ALS. Why This Matters There is no diagnostic test for ALS, … Read more

Autism, ADHD Linked to Increased Mortality Risk

All-cause mortality is significantly higher for individuals with autism spectrum disorder or attention-deficit/hyperactivity disorder than for the general population, based on data from more than 600,000 individuals. Studies of individuals with mental disorders have suggested an increased mortality risk, compared with the general population, but similar studies of individuals with autism spectrum disorder (ASD) or … Read more

Combination Antidepressant Treatment Outperforms Monotherapy

In clinical management of depression, combining a reuptake inhibitor with presynaptic alpha2-autoreceptors significantly improves treatment outcomes, compared with monotherapy, a meta-analysis found. Clinicians should consider this approach as a viable first-line treatment for severe depression and for nonresponders, a team of German researchers concluded. The findings were published online Feb. 16 in JAMA Psychiatry. Combining … Read more